Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy

Shaheen P Karim, Ron A Adelman Department of Ophthalmology and Visual Science, Yale University, New Haven, CT, USA Abstract: Central serous chorioretinopathy (CSCR) is an idiopathic disorder characterized by serous retinal detachments associated with focal leakage on fluorescein angiography and pigm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karim SP, Adelman RA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ef90d94ff62d4c9a8c096f752a3dbc31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ef90d94ff62d4c9a8c096f752a3dbc31
record_format	dspace
spelling	oai:doaj.org-article:ef90d94ff62d4c9a8c096f752a3dbc312021-12-02T07:54:33ZProfile of verteporfin and its potential for the treatment of central serous chorioretinopathy1177-54671177-5483https://doaj.org/article/ef90d94ff62d4c9a8c096f752a3dbc312013-09-01T00:00:00Zhttp://www.dovepress.com/profile-of-verteporfin-and-its-potential-for-the-treatment-of-central--a14416https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Shaheen P Karim, Ron A Adelman Department of Ophthalmology and Visual Science, Yale University, New Haven, CT, USA Abstract: Central serous chorioretinopathy (CSCR) is an idiopathic disorder characterized by serous retinal detachments associated with focal leakage on fluorescein angiography and pigment epithelial detachments. While the majority of cases improve spontaneously over several months, a significant subset of patients advance to a chronic recurrent form of the disease with diffuse pigment epitheliopathy, foveal atrophy, scarring, and permanent visual loss. Photodynamic therapy (PDT) with verteporfin has been extensively studied as a potential therapeutic option for chronic cases. Multiple prospective interventional studies have demonstrated the efficacy of PDT for CSCR with significant functional and anatomic improvements achieved. Refinement of the PDT protocol has subsequently been performed in an effort to minimize adverse effects. Anti-vascular endothelial growth factor (anti-VEGF) agents, such as bevacizumab, have been utilized in the treatment of CSCR. Recent advances in imaging and functional testing have shed further light on possible pathophysiologic mechanisms of disease and post treatment changes induced by PDT. While the body of evidence supports PDT as an efficacious and relatively safe treatment for CSCR, further evaluation of the long-term efficacy and safety of PDT, as well as protocol improvements are required. Keywords: photodynamic therapy, retinopathy, CSC, CSCRKarim SPAdelman RADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 1867-1875 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Karim SP Adelman RA Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
description	Shaheen P Karim, Ron A Adelman Department of Ophthalmology and Visual Science, Yale University, New Haven, CT, USA Abstract: Central serous chorioretinopathy (CSCR) is an idiopathic disorder characterized by serous retinal detachments associated with focal leakage on fluorescein angiography and pigment epithelial detachments. While the majority of cases improve spontaneously over several months, a significant subset of patients advance to a chronic recurrent form of the disease with diffuse pigment epitheliopathy, foveal atrophy, scarring, and permanent visual loss. Photodynamic therapy (PDT) with verteporfin has been extensively studied as a potential therapeutic option for chronic cases. Multiple prospective interventional studies have demonstrated the efficacy of PDT for CSCR with significant functional and anatomic improvements achieved. Refinement of the PDT protocol has subsequently been performed in an effort to minimize adverse effects. Anti-vascular endothelial growth factor (anti-VEGF) agents, such as bevacizumab, have been utilized in the treatment of CSCR. Recent advances in imaging and functional testing have shed further light on possible pathophysiologic mechanisms of disease and post treatment changes induced by PDT. While the body of evidence supports PDT as an efficacious and relatively safe treatment for CSCR, further evaluation of the long-term efficacy and safety of PDT, as well as protocol improvements are required. Keywords: photodynamic therapy, retinopathy, CSC, CSCR
format	article
author	Karim SP Adelman RA
author_facet	Karim SP Adelman RA
author_sort	Karim SP
title	Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
title_short	Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
title_full	Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
title_fullStr	Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
title_full_unstemmed	Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
title_sort	profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/ef90d94ff62d4c9a8c096f752a3dbc31
work_keys_str_mv	AT karimsp profileofverteporfinanditspotentialforthetreatmentofcentralserouschorioretinopathy AT adelmanra profileofverteporfinanditspotentialforthetreatmentofcentralserouschorioretinopathy
_version_	1718399137311883264

Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy

Ejemplares similares